Rehan Aziz, MD, explains how to interview older adults and which medications to use and which ones to avoid in this population.

Previously, clinicians commonly stopped opioid agonists (methadone and buprenorphine) to simplify pain control during and after surgery. New guidance from the American Society of Addiction Medicine now suggests otherwise.

An emergency department visit can be a “reachable moment” for people with unhealthy opioid use. Here, we review pharmacologic and harm-reduction strategies for use in those settings—and how to advocate for your patients when consulting with emergency clinicians.

Smartphone apps are a useful, patient-centered resource for continued substance use treatment. We’ll explore the two current FDA-cleared SUD treatment apps as well as other popular ones on the market to help you determine the best approach for discussing these apps with your patients.

Loneliness is a readily measurable phenomenon and it predicts worse outcomes in addiction treatment on the individual and population levels. What can we do in the clinic to combat loneliness and promote social cohesion?

The American Society of Addiction Medicine released updated guidelines for the management of opioid use disorder (OUD) in March, 2020. They focus on expanding access to methadone and buprenorphine. Additionally, detailed guidance is given for perioperative management of OUD and pain management in patients with OUD.

Trauma is a ubiquitous and expanding aspect of all mental health work, particularly in the age of the pandemic. Trauma Informed Care (TIC) is a necessary lens through which we need to assess and treat our patients. This article reviews the principles of TIC and offers practical tips for integrating TIC into your everyday practice.

Small studies have shown promise for treating cocaine use disorder with combination amphetamine salts/topiramate. In this larger trial, the combination was tested against a placebo.

Which patients with alcohol use disorder might benefit from gabapentin most? This randomized controlled trial focused on gabapentin’s impact on alcohol use among patients with alcohol use disorder and who had also had alcohol withdrawal symptoms in the past.